AIM ImmunoTech shares surge 15.17% after-hours on positive Phase 2 pancreatic cancer data for Ampligen.

AIM ImmunoTech surged 15.17% in after-hours trading following the release of positive Phase 2 clinical data for its drug Ampligen combined with AstraZeneca’s Imfinzi in treating metastatic pancreatic cancer. The interim update reported a median survival of 19.7 months with Ampligen versus 8.6 months under standard care, with no significant toxicity observed. The trial, conducted in collaboration with Erasmus Medical Center, highlighted encouraging immune system activation and quality-of-life improvements, reinforcing Ampligen’s potential as a first-line therapy. The company emphasized its orphan drug designations and patent protection until 2039, which could secure market exclusivity and drive long-term value. These developments align with AIM’s strategic focus on advancing Ampligen toward a Phase 3 trial, positioning it as a candidate for high-impact oncology partnerships and regulatory approval.